

1 **Characterization and comparison of immunity against MPXV for individuals infected**
2 **with MPXV or vaccinated with modified vaccinia Ankara vaccines**

3

4 **Authors**

5 Aurélie Wiedemann^{1,2‡}, Mathieu Surénaud^{1,2‡}, Mathieu Hubert³, José-Luis Lopez Zaragoza⁴,
6 Alexandre Ribeiro^{1,2}, Cécile Rodrigues^{1,2}, Emile Foucat^{1,2}, Harouna Diombera^{1,4}, Corinne
7 Krief^{1,2}, Olivier Schwartz^{1,3}, Jean-Daniel Lelièvre^{1,2,4}, and Yves Lévy^{1,2,4*}

8 **Affiliations**

9 1. Vaccine Research Institute, Université Paris-Est Créteil, France

10 2. INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy,
11 Créteil, France

12 3. Institut Pasteur, Université Paris Cité, Virus and Immunity Unit, CNRS UMR3569,
13 75015 Paris, France

14 4. Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier,
15 Service Immunologie Clinique, Créteil, France

16

17 ***Correspondence:** Pr. Yves Lévy, Vaccine Research Institute, INSERM U955, Hopital Henri
18 Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France, Phone: +33 (0) 1 49
19 81 44 42, Fax: +33 (0) 1 49 81 24 69, E-mail: yves.levy@aphp.fr

20 [‡]these authors contributed equally

21

22 **Abstract (250 words)**

23 The 2022 monkeypox virus (MPXV) outbreak has revitalized questions about immunity against MPXV
24 and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in
25 individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara vaccine
26 (MVA)-BN or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody (NAb)
27 responders was higher among MPXV-infected individuals than MVA vaccinees. Both MVA vaccines
28 induced similar and strong humoral responses. Similarly, we show a higher frequency and magnitude
29 (5-fold) of T-cell responses, mainly mediated by CD8⁺ T cells, against a peptide pool containing
30 selected sequences from MPXV, Variola, and VAC-V in MPXV-infected individuals than MVA
31 vaccinees. We describe a hierarchy of cross-reactive T-cell responses against five peptide pools that
32 are highly homologous between VAC-V and MPXV 2022, with the highest frequency of responders
33 against MVA-121L and MVA-018L proteins. Both vaccines stimulated a notable frequency of
34 polyfunctional CD4⁺ and CD8⁺ T-cell responses, with a subset of CD4⁺ T cells showing a mixed
35 cytokine profile. Finally, we found that smallpox vaccination in childhood positively affected humoral
36 but not T-cell vaccine responses, whereas these responses were not affected in people living with
37 HIV. These findings contribute to deciphering and monitoring the profile of immunity to MPXV and
38 MVA. In the context of a potential threat of the reemergence of smallpox following bioterrorism, the
39 diversification and availability of potent vaccines is crucial. The comparable immunogenicity of both
40 MVA vaccines emphasizes the potential utility of MVA-HIVB as a valuable new tool for controlling
41 MPXV outbreaks.

42

43

44

45 Introduction

46 Mpox virus (MPXV, formerly known as monkeypox) is a zoonotic poxvirus disease that is usually
47 endemic to countries in West and Central Africa and caused by an Orthopoxvirus (OPXV). This viral
48 genus includes smallpox. The cessation of massive vaccination in 1980 after the eradication of
49 smallpox has increased the risk of the emergence of OPXV in humans. Since then, the number of
50 cases and geographic range have increased substantially, possibly related to the waning of smallpox
51 vaccine-induced immunity. The recent outbreak in 2022 is linked to a genotypically distinct MPXV
52 related to West Africa. It was first detected in Europe and then spread throughout the world ¹. The
53 large number of cases in more than 110 countries represented a global threat. This prompted the
54 World Health Organization to claim a public health emergency of international concern.

55 The recent 2022 mpox outbreak was unusual, with an absence of direct links to endemic countries and
56 sustained human-to-human transmission. Mpox causes an illness with a febrile rash in humans,
57 similar to but milder than smallpox. Populations at risk were people living with HIV (PLWHIV), men
58 who have sex with men (MSM), bisexuals, and young individuals without previous smallpox
59 vaccination during childhood ^{2, 3, 4, 5}. The case fatality rate was low (0.1%) relative to previous
60 outbreaks that occurred in West (lethality rate 1-6%) and Central Africa (11%), but infections were
61 severe and the lethality rates were high among PLWHIV with advanced infection ⁴.

62 Three generations of vaccines based on vaccinia virus (VACV) were originally developed against
63 smallpox ⁶. The first-generation vaccine is comprised of live VACV, (e.g., Dryvax) and was used for
64 the eradication of smallpox. ACAM2000 is a second-generation vaccine, also based on live VACV
65 (Emergent Product Development Gaithersburg, MD, USA). This vaccine offers an improved safety
66 profile and has been made accessible to healthcare workers and individuals aged 18 years or older.
67 During the recent outbreak, vaccination campaigns were based on a third generation of a safer
68 vaccine consisting of an attenuated modified vaccinia virus Ankara (MVA) and is incapable of
69 replication in humans ⁷. This vaccine, produced by Bavarian Nordic (MVA-BN, commercialized under
70 the names of IMVANEX or JYNNEOS), is the only vaccine approved for mpox prevention. Previous
71 studies showed these second- and third-generation vaccines to be highly immunogenic ^{8, 9, 10, 11, 12}.
72 However, data demonstrating protection by IMVANEX has only been shown in animal models ^{7, 13, 14}.

73 ^{15, 16}. Furthermore, this vaccine is available in only limited quantities ¹⁷, highlighting the need to develop
74 other vaccine candidates to control the expansion of cases in an epidemic situation.

75 The recent report of new cases of MPXV reinfection in MVA-BN-vaccinated individuals ^{18, 19} is a true
76 concern and raises questions about the protective and durable immunity conferred by this attenuated
77 vaccine. Dryvac-induced B- and T-cell immunity can persist for years (> 50 years) ^{20, 21, 22, 23, 24}. Recent
78 studies have shown low-level and rapid waning of neutralizing antibodies after MVA-BN
79 (IMVANEX/JYNNEOS) vaccination ^{25, 26}. MVA-BN does not elicit potent maturation of the B-cell
80 repertoire, a critical process for neutralization of the virus and durability of the response ²⁷, raising the
81 question of the respective roles of B-cell and cellular immunity in vaccine protection. Few studies have
82 investigated T-cell responses against MPXV in humans ^{28, 29, 30}. Data concerning the quality of immune
83 responses to MPXV and the currently used third generation of MVA-based vaccines are limited ²⁷.

84 We recently examined the neutralizing antibody (NAb) responses to MVA and MPXV in convalescent
85 patients who had recovered from mpox infection, those who have received historic smallpox
86 vaccination, and those who had been administered MVA-based vaccines, including an experimental
87 MVA-HIVB vaccine ³¹. A comparison of B-cell responses showed large differences in NAb levels
88 between the various cohorts of individuals. High NAb titers were measured in ancient smallpox-
89 vaccinated MPXV-infected patients, suggesting potential cross-protection mediated by hybrid
90 immunity. Here, we extended these data by characterization of the cellular immunity of individuals
91 infected with MPXV or receiving MVA-based vaccines. We describe the cross reactivity and the impact
92 of historical smallpox vaccination and HIV status of participants on these responses.

93

94 **Results**

95 **Participants enrolled in the study**

96 We analyzed peripheral blood mononuclear cells and sera from 61 individuals, including eight MPXV-
97 infected individuals (21 days after symptoms onset and noted as being convalescent, Conv.) and 53
98 MVA-BN vaccine recipients. Individuals born after 1980, the data of cessation of smallpox vaccination,
99 received two doses of the vaccine, with an interval of 28 to 35 days, whereas older individuals (born
100 before 1980 and who received a smallpox vaccination during childhood) received a single dose
101 according to national recommendations. The median age of MPXV-infected and vaccinated individuals
102 was 33 [24-47] and 43 [32-56] years, respectively. All participants were male. Among them, 30/61
103 individuals were living with HIV (PLWHIV) (6/8 MPXV-infected and 24/53 vaccinated, all under
104 antiretroviral treatment and with a CD4 count > 200/mm³). The study also included ten healthy
105 volunteers (median age 24 [21-26], 70% male), who received two doses (separated by 8 weeks) of the
106 MVA-HIVB, candidate MVA vaccine carrying HIV epitopes in the setting of the ANRS VRI01 clinical
107 trial³².

108 **Neutralizing antibodies induced by MPXV infection and MVA-BN and MVA-HIVB vaccination**

109 We quantified the neutralizing activity of sera from MPXV-infected and MVA-vaccinated individuals.
110 We used two assays to measure neutralization titers against MVA-GFP and an authentic clinical
111 MPXV strain isolated from a typical lesion of a French patient infected in June 2022 grown on Vero E6
112 cells (GenBank accession number OQ249661), with or without complement supplementation, as
113 recently reported by our group³¹ (Figure 1). We detected anti-MVA NAb in 50% of MPXV-infected
114 individuals (median ED50: 38.4). Ninety-five percent (median ED50 of 128.8) of individuals born
115 before 1980 and 13% (median ED50 of 15) born after were neutralizers after a single dose of MVA-
116 BN, highlighting the importance of priming during childhood. The second dose of vaccine increased
117 the percentage of neutralizers among younger individuals to 72% (median ED50: 201). The addition of
118 complement increased NAb titers and the percentage of responders, with 100% neutralizers detected
119 among MPXV-infected (median ED50: 594.2) and older vaccinated individuals (median ED50: 445.9)
120 and 94% among the younger vaccinees (median ED50: 669.5) two weeks after full vaccination. We
121 further assessed the immunogenicity of MVA as a vaccine platform by measuring NAb levels in sera
122 from healthy donors, all born after 1980, who received two doses of the MVA-HIVB vaccine candidate
123 in the VRI01 trial. Two weeks after the second dose, 90% were responders, regardless of the

124 presence of complement (median ED₅₀: 1465 and 460.3, with and without complement, respectively)
125 (Figure 1A).

126 The NAb titers and frequency of responders were low in the absence of complement in the MPXV
127 assay³¹. Among MPXV-infected individuals, 25% (2/8) and 88% (7/8) were responders in assays
128 without and with complement, respectively (Figure 1B). Among individuals who received a single MVA-
129 BN injection (older individuals), none were responders in the absence of complement, while 45% were
130 responders in the presence of complement. There were no responders after one or two doses of MVA-
131 BN (younger individuals) in assays without complement, whereas 27% and 44% were neutralizers at
132 these time points in the presence of complement. We detected 20% (2/10) and 50% neutralizers
133 among MVA-HIVB vaccinees in assays without and with complement, respectively (Figure 1B).

134 **The Pan-PXV peptide pool elicits T-cell responses in MPXV-infected individuals and MVA-BN** 135 **and experimental MVA-HIVB vaccinees**

136 We next assessed T-cell immune responses using the *ex vivo* IFN- γ ELISpot assay and a
137 commercially available pan-poxviridae peptide pool containing selected sequences from monkeypox,
138 variola, and vaccinia viruses (Pan-PXV pool from JPT Peptide Technologies). The frequency of
139 responders was 88% (7/8) among MPXV-infected individuals. After one dose of MVA-BN, 50% (10/20)
140 and 53% (8/15) were responders among older and younger individuals, respectively. In the younger
141 group, 72% (13/18) were responders after the second vaccine dose. Eighty percent (8/10) were
142 responders after two doses of the MVA-HIVB vaccine (Figure 2A). We then compared T-cell
143 responses specific to Pan-PXV between MPXV-infected patients and individuals who received full
144 vaccination (1 or 2 doses, based on their history of smallpox vaccination during childhood,) of MVA-
145 BN, or two doses of MVA-HIVB. Infected patients showed a significantly higher median number of
146 spot-forming cells (SFC/10⁶ cells) against the Pan-PXV pool than fully vaccinated MVA-BN individuals
147 (540 [160-1133] vs 96.5 [22-180], P=0.0071), whereas the magnitude was not significantly different
148 from that of recipients of MVA-HIVB (P=0.5829) (Figure 2B).

149 The functionality of Pan-PXV-specific CD4⁺ and CD8⁺ T-cell responses was assessed by intracellular
150 cytokine staining (ICS) (Gating strategy is shown in supplementary Figure 2). We evaluated the
151 production of IFN- γ , IL-2, TNF, and IL-4/IL-13/IL-10 (Th2/regulatory cytokines) by CD4⁺ T cells and
152 IFN- γ , IL-2, and TNF by CD8⁺ T cells. Interestingly, only Pan-PXV-specific CD8⁺ T cells were detected
153 *ex vivo*. The median [IQR] frequency of CD8⁺ T-cell responses was 0.67% [0.5-0.8] for MPXV-infected

154 individuals, 0.17% [0.1-0.2] for older individuals, 0.18% [0.1-0.2] and 0.18% [0.09-0.4] for younger
155 individuals after one or two doses, respectively, and 0.19% [0.1-0.5] for MVA-HIVB recipients (Figure
156 2C). These values were significantly different from those for unstimulated conditions ($P < 0.05$) for all
157 comparisons. Globally, the median magnitude of CD8⁺ Pan-PXV-specific T cells was higher for
158 infected patients than for MVA-BN-vaccinated individuals (0.45% [0.3-0.6] vs 0.06% [0.04-0.14],
159 $P = 0.0155$) (Figure 2D). Polyfunctional CD8⁺ T-cell specific responses to the Pan-PXV peptide pool
160 (producing up to 3 cytokines: IFN- γ ± IL-2 ± TNF) were detectable in all groups. MPXV-infected
161 individuals exhibited a low frequency (6%) of CD8⁺ T cells simultaneously producing three cytokines
162 and 70% double positive IFN- γ ⁺/TNF⁺ CD8⁺ T cells. Single positive CD8⁺ T cells were predominantly
163 IFN- γ ⁺. Older individuals who received one dose of MVA-BN vaccine showed a low frequency (6%) of
164 triple positive CD8⁺ T cells, a higher frequency of double positive (IFN- γ ⁺TNF⁺) (43%) CD8⁺ T cells and
165 similar levels of single IFN- γ and TNF-producing cells (23% for IFN- γ and 21% for TNF). Younger
166 vaccinees exhibited clearly higher frequencies of triple- (25%) and double- (45%) positive CD8⁺ T cells
167 after one dose of MVA-BN. After two doses of the MVA-BN or MVA-HIVB vaccines, the functional
168 profiles of Pan-PXV CD8⁺ T cells were similar, with a high proportion of triple- (29% and 27%,
169 respectively) and double- (35% and 44%, respectively) positive CD8⁺ T cells (Figure 2C).

170 **The MVA peptide pools elicit T-cell responses in MPXV-infected individuals and MVA-BN and** 171 **experimental MVA-HIVB vaccinees**

172 We next used five PepMix pools (MVA-018L, MVA-074R, MVA-093L, MVA-105L, and MVA-121L),
173 consisting of 15-mer peptides, overlapping by 11 amino acids, covering different proteins of MVA
174 (Supplementary Table 1), to deeply characterize T-cell immune responses against vaccinia virus and
175 enable a comprehensive comparison between individuals vaccinated with the MVA-BN and MVA-HIVB
176 vaccines.

177 The MVA proteins exhibit a high degree of similarity with both the MVA-BN and MVA-HIVB vaccines
178 (>99%) and with the vaccinia virus Lister strain (>98%) used in historical smallpox vaccinations. These
179 MVA proteins show significant conservation in the MPXV 2022 sequences (>94%). We first evaluated
180 the proportion of IFN- γ responders to the MVA global peptide pool (i.e., sum of the five Pepmix peptide
181 pools) by *ex-vivo* IFN- γ ELISPOT assay. IFN- γ responders were 75% (6/8) for MPXV-infected
182 individuals, 60% (12/20) for older individuals who received one dose of MVA-BN, and 60% (9/15) and

183 83% (15/18) for younger individuals after the first and second dose of the MVA-BN vaccine,
184 respectively. One hundred percent (10/10) in the two-dose MVA-HIVB vaccine group were
185 responders. The median magnitude (SFC/10⁶ cells) of the response was 107.5 [39-297] for
186 convalescent patients, 84.5 [25-195] for older individuals who received one dose, and 88 [34-236] and
187 221.5 [88-465] for younger individuals after one and two doses of MVA-BN vaccine, respectively.
188 Individuals fully vaccinated with the MVA-HIVB vaccine showed the highest response (248 SFC/10⁶
189 cells [153-1010]) (Figure 3A).

190 We sought to assess the frequency of IFN- γ responders to individual peptide pools between the
191 various groups (Figure S1). We found a higher frequency of responders to the MVA-121L and MVA-
192 018L peptide pools (41% and 34%, respectively) than to the MVA-093L, -074R, and -105L peptide
193 pools (18%, 12%, and 8%, respectively) (Figure 3B). We then analyzed the breadth of T-cell
194 responses among IFN- γ responders within the five different MVA peptide pools. We found T-cell
195 responders to each MVA peptide pool, but with differences between groups. For example, we detected
196 T-cell responses against the MVA-105L peptide pool for younger individuals vaccinated with MVA-BN
197 and MVA-HIVB but not for MPXV-infected and older individuals with a history of smallpox vaccination
198 who received one dose of MVA-BN. Moreover, the MVA-105L peptide pool was mostly targeted by
199 individuals who received the MVA-HIVB vaccine (71%). The MVA-018L and MVA-093L peptide pools
200 were mainly targeted by individuals who received two doses of either the MVA-BN (33% and 25%
201 respectively) or MVA-HIVB (35% and 33%, respectively) vaccines. The MVA-074R peptide pool was
202 mostly targeted by MPXV-infected individuals (40%). Finally, responses against the MVA-121L peptide
203 pool were equally detected for all groups (Figure 3C).

204 **The MVA-121L and MVA-018L peptide pools elicit polyfunctional CD4⁺ and CD8⁺ T-cell** 205 **responses in MVA-vaccinated recipients**

206 We further characterized the CD4⁺ and CD8⁺ T-cell responses induced by the MVA peptide pools by
207 ICS (Figure 4 and supplementary figure 2 for representative dot plots). Responses were detected
208 solely for vaccinees (MVA-BN and MVA-HIVB) and were dominated by two peptide pools: MVA-121L
209 and MVA-018L. CD4⁺ T-cell responses to the MVA-121L peptide pool were significant ($P < 0.05$ for all
210 comparisons with non-stimulated conditions) for older (one dose) and younger (one and two doses)
211 MVA-BN and MVA-HIVB (two doses) vaccinated individuals, with a high proportion of polyfunctional
212 CD4⁺ T cells with a mixed cytokine profile simultaneously producing up to four cytokines (IFN- γ ±IL-

213 2±IL-4/IL-13/IL-10±TNF). Polyfunctional CD4⁺ T-cell frequencies ranged between 60% for younger
214 individuals who received one dose of MVA-BN to 76% for the MVA-HIVB vaccinees. Interestingly, the
215 functional profile of CD4⁺ T-cell responses against MVA-121L was similar for recipients of two doses
216 of MVA-BN or MVA-HIVB. Among specific CD4⁺ T cells producing only one cytokine, CD4⁺TNF⁺ cells
217 were predominant (Figure 4A). Two doses of MVA-BN and MVA-HIVB vaccines elicited MVA-121L-
218 specific CD8⁺T cells (P=0.02 and P=0.004 compared to unstimulated conditions, respectively), with
219 mostly IFN-γ⁺ single positive CD8⁺ T cells (Figure 4B). In addition to MVA-121L, MVA-018L also
220 induced detectable CD8⁺ T-cell responses following two doses of the MVA-BN and MVA-HIVB
221 vaccines (P=0.0009 and P<0.0001 compared to unstimulated conditions, respectively), with a
222 predominant proportion of polyfunctional CD8⁺ T cells simultaneously producing up to three cytokines
223 (47% and 66% for MVA-BN and MVA-HIVB, respectively). Among specific CD8⁺ T cells producing two
224 cytokines, the profile was similar for both groups, consisting mostly of IFN-γ/TNF-producing cells. The
225 frequencies of IFN-γ⁺ single-positive CD8⁺ T cells were 49% for the MVA-BN group and 28% for the
226 MVA-HIVB group (Figure 4B).

227 **MVA-BN vaccination in HIV-positive and HIV-negative Individuals**

228 Finally, we evaluated the immune response of PLWHIV under successful antiretroviral therapy to
229 MVA-BN vaccination. We found NAb titers against MVA and MPXV, as well as T-cell responses
230 against the Pan-PXV and MVA peptide pools, for fully MVA-BN-vaccinated PLWHIV to not be
231 significantly different from those of non-HIV-infected individuals, either after one (for older individuals)
232 or two doses (for younger individuals) (Figure 5).

233

234 **Discussion**

235 The recent outbreak of mpox infection has revitalized questions about the quality and durability of
236 humoral and cellular responses against OPXV and the efficacy of the approved MVA-based vaccine
237 (IMVANEX) deployed since May 2022 for populations at risk of infection. We analyzed antibody and
238 cellular responses against MPXV and MVA in subjects infected during the recent mpox-2022 outbreak
239 or vaccinated with the MVA-BN (IMVANEX) vaccine or an experimental MVA-HIVB vaccine
240 (ANRS/VRI01 trial; NCT02038842)³². We provide insights about the cross reactivity of the humoral
241 and cellular responses induced by MVA-based vaccination and MPXV infection and the impact of
242 historical smallpox vaccination on cellular immunity following MPXV infection or MVA vaccination, in
243 particular among PLWHIV.

244 To study protective antibody-based immunity, we measured Nabs against MVA and MPXV. As
245 recently shown^{31, 33}, the presence of complement enhanced the sensitivity of Nab detection. We found
246 a higher frequency of MPXV and MVA responders among MPXV-infected individuals (88-100%) three
247 weeks after the onset of symptoms than among individuals vaccinated with MVA. The proportion of
248 MVA neutralizers among the recipients of two doses of MVA-HIVB or MVA-BN was roughly similar
249 (90% and 94%, respectively), whereas the MVA Nab titers were approximately 2.2-fold higher after the
250 second dose of MVA-HIVB than that of MVA-BN. Despite homology between MVA and MPXV, only
251 around 45% of fully vaccinated older and younger MVA-BN-vaccinated individuals exhibited weak
252 MPXV neutralization activity, a frequency similar to that for MVA-HIVB vaccinees (50%). Thus, despite
253 potential differences in the MVA-BN and MVA-HIVB strains, preparation methods, and doses
254 administered, these two vaccines elicited strong and similar humoral responses against MVA and
255 MPXV. This observation supports the development of future MVA-based vaccines against MPXV³⁴.

256 One dose of MVA-BN led to a higher frequency of MVA neutralizers and higher titers (8.5-fold) for
257 individuals born before 1980 than those born after (95% versus 26%), underscoring the importance of
258 childhood smallpox vaccination. Smallpox vaccination of the French population stopped in 1979 and
259 smallpox was declared to be eradicated worldwide in 1980. Our observation suggests that MVA-BN
260 recalled long-term memory B-cell responses and supports the persistence of smallpox-specific B cells
261 in the absence of re-exposure to smallpox antigens. Several studies have demonstrated the presence
262 of long-lived smallpox-specific B cells up to 50 to 75 years after vaccination^{22, 35, 36, 37} and the stability

263 of anti-vaccinia antibody serum titers in humans for more than 80 years after first vaccination^{17, 20, 37}.
264 Finally, the significant increase in the rate of MVA (from 26% to 72%) and MPXV (0% to 44%)
265 responders following a second boost of MVA-BN among younger individuals reinforces the need of a
266 complete vaccination scheme to improve protective immunity in a “naïve” population.

267 In humans, it is likely that both humoral and cell-mediated immunity are important for protection
268 against OPXV. Few studies have investigated or compared cellular immune responses to MPXV- and
269 MVA-based vaccines^{27, 28} and more in-depth analyses of the antigens recognized by T cells are
270 warranted. In parallel to neutralizing antibody responses, we found a higher frequency and magnitude
271 (5-fold) of T-cell responses against peptide pools containing selected sequences from MPXV, variola,
272 and vaccinia viruses (Pan-PXV) for MPXV-infected than MVA-vaccinated individuals. ICS assay
273 showed that this response was mediated by CD8 T cells. This observation differs from those of a
274 recent study²⁷ and can be explained by two principal factors. First, the cellular assays used; Cohn and
275 colleagues adopted a combined AIM/ICS assay while we employed a two-step approach, starting with
276 an IFN-g ELISpot and subsequently using ICS assays, despite the latter being less sensitive in
277 comparison to an AIM assay. Our aim in employing this strategy was to deeply characterize the
278 functionality of mpox-specific CD4 and CD8 T cells, rather than solely focusing on assessing the
279 frequency of these cell populations. Secondly, the composition of the peptide pools, they used 2
280 megapools (one megapool of 238 CD8 T-cell epitopes, of which 82% are 100% conserved in MPXV,
281 and another megapool of 300 CD4 T-cell epitopes, of which 94% are 100% conserved in MPXV). In
282 contrast, we employed a Pan-PXV peptide pool containing 127 epitopes, comprising 107 CD8 T-cell
283 epitopes and 20 CD4 T-cell epitopes, with 96% exhibiting complete conservation in MPXV and 94% in
284 MVA.

285 In contrast to antibody responses, the frequency of T-cell responders following the administration of
286 MVA-BN was found to be the same for both older and younger vaccinated individuals (approximately
287 50%). This suggests that the impact of smallpox vaccination in childhood on T-cell responses may be
288 relatively low. Analysis of the quality of Pan-PXV specific T cells showed these responses to be mainly
289 mediated by CD8⁺ T cells and confirmed a higher frequency of such T-cell responses among MPXV-
290 infected individuals. Interestingly, MPXV infection was characterized by a high frequency of CD8⁺ cells
291 simultaneously producing TNF/IFN- γ , whereas full vaccination with IMVANEX and MVA-HIVB induced

292 a higher frequency of polyfunctional Th1 CD8⁺ T cells simultaneously producing three cytokines (IL-
293 2+IFN- γ +TNF).

294 Despite high genetic similarity between MVA and MPXV-2022^{28, 38}, the potential impact of variations in
295 T-cell epitopes on the cross reactivity induced by MVA-based vaccination and MPXV infection is yet to
296 be determined. To analyze the cross-reactivity of T-cell responses in more depth, we selected five
297 pools of peptides spanning five highly homologous regions between the two MVA vaccines and the
298 original vaccinia Lister strain used in historical smallpox vaccination (>98%) and MPXV 2022
299 sequences (>94%). Using the Elispot-iFN- γ assay as a screening test, we found a hierarchy of T-cell
300 responses against these peptide pools ranging from MVA-121L and MVA-018L (41% and 34%
301 responders, respectively) to MVA-105L (8% responders). Indeed, the MVA-121L protein corresponds
302 to the A10L vaccinia protein and is known to contain a high number of T-cell epitopes (27 CD4⁺ and 1
303 CD8⁺ T-cell epitopes)^{28, 38}, which are highly conserved (100%) in MVA-BN (21 epitopes) and MPX-
304 2022 (25 epitopes). MVA-018L corresponds to the C7L vaccinia protein and contains two CD8⁺ T-cell
305 epitopes^{28, 38}, including one (KVDDTFYYV) that is relatively dominant in HLA-A2⁺ individuals³⁹. The
306 observed lower frequency of responders to MVA-18L among MPXV-infected patients relative to MVA-
307 vaccinated individuals can be explained by the presence of the D77Y mutation in this dominant
308 epitope in the MPXV-2022 sequence. Similarly, the frequency of T-cell responders to the MVA-093L
309 peptide pool, which targets the H3L vaccinia protein, among MPXV-infected individuals was low,
310 despite the presence of eight CD4⁺ and four CD8⁺ T-cell epitopes^{28, 38}. However, nine of these 12
311 epitopes contain at least one mutation in the MPXV-2022 sequence. Finally, T-cell responses to the
312 MVA-105L (corresponding to the D8L vaccinia protein) peptide pool were infrequent among MVA-
313 vaccinated individuals (8%) and not detected among MPXV-infected subjects. This is consistent with a
314 single described CD4⁺ T-cell epitope in this protein^{28, 38}, which contains two mutations in the MPXV-
315 2022 sequence. Overall, although the peptide regions exhibit significant homology, the variations
316 observed among different groups of individuals align with the distinctions observed between the
317 evolution of MVA and MPXV. Beyond a descriptive profile of T-cell responses, these data help to
318 enrich the arsenal of peptide tools for the future immunological evaluation of OPXV infection and
319 vaccination.

320 The potential threat of the reemergence of smallpox following an act of bioterrorism or of MPXV raises
321 the question of the diversification and availability of potent vaccines. We took the opportunity to
322 analyze B- and T-cell responses against the MVA vector of participants who received two doses of an
323 MVA-based HIV vaccine candidate (MVA- HIVB) in the ANRS VRI01 trial ³². We show ³¹ and confirm
324 that the MVA-HIVB vaccine elicits somewhat higher levels of anti-MVA Nabs in individuals born before
325 1980 than after IMVANEX administration. Moreover, we extend these data, showing that both
326 vaccines induce a high frequency of polyfunctional CD4⁺ and CD8⁺ T-cell responses against MVA-
327 121L and MVA-018L, with a high proportion of polyfunctional CD4⁺ T cells with a mixed cytokine
328 profile simultaneously producing up to four Th1/Th2 cytokines, a population of cells described in
329 smallpox vaccination ⁴⁰. Overall, the T-cell responses triggered by two doses of MVA-HIVB were either
330 similar or occurred at a higher frequency than those to MVA-BN. These findings provide reassurance
331 concerning the potential production of clinical batches of this vector, if needed.

332 Although our study was not designed to compare the potency of vaccination between different groups
333 of patients, we were able to show that Nab titers against both MVA and MPXV, as well as T-cell
334 responses against the Pan-PXV and MVA peptide pools, were not impaired in PLWHIV, regardless of
335 age. It's worth noting that individuals infected with HIV-1 who participated in this study were
336 undergoing antiretroviral therapy and maintained a robust immune profile, characterized by CD4 T
337 lymphocyte counts exceeding 200 cells/mm³ and an undetectable plasma HIV RNA viral load (below
338 20 copies/ml). This favorable immunological status may account for the absence of differences in
339 vaccine response magnitude when compared to individuals without HIV infection. Although reassuring,
340 these data should be viewed in light of the recent observation of MPXV reinfection in previously
341 vaccinated individuals and underscore the need to repeat boosting according to recent
342 recommendations.

343 This study had several limitations. Individuals were enrolled after infection (three weeks, on average,
344 after symptoms) and following vaccination. We did not evaluate their baseline immune status.
345 However, the results within each group were homogeneous and allowed statistical comparisons
346 between groups. We evaluated the levels of neutralizing antibodies, but we did not assess the levels
347 of antigen-binding antibodies. Additionally, we did not evaluate antibody effector functions due to the
348 unavailability of standardized kits for conducting these specific assays. We describe T-cell responses

349 against peptides pools but did not perform epitope mapping because of the limited amount of the
350 blood samples and lack of patient HLA information. We assessed T-cell responses using ex vivo
351 stimulations. The lack of response in some cases may be attributed to the lower sensitivity of the ex
352 vivo ICS assay. However, we also conducted an ELISPOT assay, which has a high level of sensitivity,
353 even though it cannot distinguish between CD4 and CD8 responses. Finally, we did not perform long-
354 term follow up of B- or T-cell responses to assess the durability of the responses, either for MPXV-
355 infected individuals or MVA-vaccinated individuals.

356

357 **References**

358

359 1. Wang L, Shang J, Weng S, Aliyari SR, Ji C, Cheng G, et al. Genomic annotation and
360 molecular evolution of monkeypox virus outbreak in 2022. *Journal of Medical Virology* 2022, 95(1).

361

362 2. Alarcón J, Kim M, Terashita D, Davar K, Garrigues JM, Guccione JP, et al. An Mpox-Related
363 Death in the United States. *New England Journal of Medicine* 2023, 388(13): 1246-1247.

364

365 3. Mahase E. Mpox: Clinicians identify severe form with high mortality in advanced HIV patients.
366 *Bmj* 2023: p422.

367

368 4. Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, et al.
369 Mpox in people with advanced HIV infection: a global case series. *The Lancet* 2023, 401(10380): 939-
370 949.

371

372 5. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox
373 Virus Infection in Humans across 16 Countries — April–June 2022. *New England Journal of Medicine*
374 2022, 387(8): 679-691.

375

376 6. Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review.
377 *The Lancet Infectious Diseases* 2022, 22(12): e349-e358.

378

379 7. Volz A, Sutter G. Modified Vaccinia Virus Ankara. 2017, 97: 187-243.

380

381 8. Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, et al. Evaluation of
382 smallpox vaccines using variola neutralization. *Journal of General Virology* 2009, 90(8): 1962-1966.

383 9. Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the
384 safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults.
385 *Vaccine* 2009, 27(10): 1637-1644.

386

387 10. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, et al. Clinical and immunologic
388 responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax®
389 challenge. *Vaccine* 2007, 25(51): 8562-8573.

390

- 391 11. Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, et al. A
392 randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at
393 various doses in adults with a history of AIDS. *Vaccine* 2020, 38(11): 2600-2607.
- 394
- 395 12. Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, et al. Phase 3 Efficacy Trial of
396 Modified Vaccinia Ankara as a Vaccine against Smallpox. *New England Journal of Medicine* 2019,
397 381(20): 1897-1908.
- 398
- 399 13. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a
400 highly attenuated MVA smallpox vaccine and protection against monkeypox. *Nature* 2004, 428(6979):
401 182-185.
- 402
- 403 14. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, et al. Rapid protection in a
404 monkeypox model by a single injection of a replication-deficient vaccinia virus. *Proceedings of the*
405 *National Academy of Sciences* 2008, 105(31): 10889-10894.
- 406
- 407 15. Hatch GJ, Graham VA, Bewley KR, Tree JA, Dennis M, Taylor I, et al. Assessment of the
408 Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in
409 *Cynomolgus Macaques*. *Journal of Virology* 2013, 87(14): 7805-7815.
- 410
- 411 16. Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Ariei NG, Abu Ahmad W, et al. Real-
412 world effectiveness of a single dose of mpox vaccine in males. *Nature Medicine* 2023, 29(3): 748-752.
- 413
- 414 17. Taub DD, Ershler WB, Janowski M, Artz A, Key ML, McKelvey J, et al. Immunity from
415 Smallpox Vaccine Persists for Decades: A Longitudinal Study. *The American Journal of Medicine*
416 2008, 121(12): 1058-1064.
- 417
- 418 18. Golden J, Harryman L, Crofts M, Muir P, Donati M, Gillett S, et al. Case of apparent mpox
419 reinfection. *Sexually Transmitted Infections* 2023, 99(4): 283-284.
- 420
- 421 19. Jamard S, Handala L, Faussat C, Vincent N, Stefic K, Gaudy-Graffin C, et al. Resurgence of
422 symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster. *Infectious*
423 *Diseases Now* 2023, 53(4): 104714.

424

425 20. Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox
426 vaccination. *Immunological Reviews* 2006, 211(1): 320-337.

427

428 21. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire Fo, et al. Distinct
429 Time Effects of Vaccination on Long-Term Proliferative and IFN- γ -producing T Cell Memory to
430 Smallpox in Humans. *Journal of Experimental Medicine* 2004, 199(11): 1585-1593.

431

432 22. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting Edge: Long-Term B
433 Cell Memory in Humans after Smallpox Vaccination. *The Journal of Immunology* 2003, 171(10): 4969-
434 4973.

435

436 23. Demkowicz WE, Littau RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived
437 responses to vaccinia virus. *Journal of Virology* 1996, 70(4): 2627-2631.

438

439 24. Kennedy JS, Greenberg RN. IMVAMUNE®: modified vaccinia Ankara strain as an attenuated
440 smallpox vaccine. *Expert Review of Vaccines* 2014, 8(1): 13-24.

441

442 25. Cosma A, Buhler S, Nagaraj R, Staib C, Hammarin A-L, Wahren B, et al. Neutralization
443 Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a
444 High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus. *Clinical
445 and Vaccine Immunology* 2004, 11(2): 406-410.

446

447 26. Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, van Royen ME, Götz H, et al. Low
448 levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
449 *Nature Medicine* 2022, 29(1): 270-278.

450

451 27. Cohn H, Bloom N, Cai GY, Clark JJ, Tarke A, Bermúdez-González MC, et al. Mpox vaccine
452 and infection-driven human immune signatures: an immunological analysis of an observational study.
453 *The Lancet Infectious Diseases* 2023.

454

455 28. Grifoni A, Zhang Y, Tarke A, Sidney J, Rubiro P, Reina-Campos M, et al. Defining antigen
456 targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. *Cell Host &*
457 *Microbe* 2022, 30(12): 1662-1670.e1664.

458

459 29. Agrati C, Cossarizza A, Mazzotta V, Grassi G, Casetti R, De Biasi S, et al. Immunological
460 signature in human cases of monkeypox infection in 2022 outbreak: an observational study. *The*
461 *Lancet Infectious Diseases* 2023, 23(3): 320-330.

462

463 30. Adamo S, Gao Y, Sekine T, Mily A, Wu J, Storgård E, et al. Memory profiles distinguish cross-
464 reactive and virus-specific T cell immunity to mpox. *Cell Host & Microbe* 2023, 31(6): 928-936.e924.

465

466 31. Hubert M, Guivel-Benhassine F, Bruel T, Porrot F, Planas D, Vanhomwegen J, et al.
467 Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. *Cell*
468 *Host & Microbe* 2023, 31(6): 937-948.e934.

469

470 32. Richert L, Lelièvre J-D, Lacabaratz C, Hardel L, Hocini H, Wiedemann A, et al. T Cell
471 Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost
472 Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm
473 Phase I/II ANRS VRI01 Trial. *The Journal of Immunology* 2022, 208(12): 2663-2674.

474

475 33. Yefet R, Friedel N, Tamir H, Polonsky K, Mor M, Cherry-Mimran L, et al. Monkeypox infection
476 elicits strong antibody and B cell response against A35R and H3L antigens. *iScience* 2023, 26(2):
477 105957.

478

479 34. Raadsen MP, Dahlke C, Fathi A, Lamers MM, van den Doel P, Zaeck LM, et al. Monkeypox
480 Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia
481 Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. *The Journal of*
482 *Infectious Diseases* 2023.

483

484 35. Chappert P, Huetz F, Espinasse M-A, Chatonnet F, Pannetier L, Da Silva L, et al. Human anti-
485 smallpox long-lived memory B cells are defined by dynamic interactions in the splenic niche and long-
486 lasting germinal center imprinting. *Immunity* 2022, 55(10): 1872-1890.e1879.

487

488 36. Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, et al. Cross-Neutralizing and
489 Protective Human Antibody Specificities to Poxvirus Infections. *Cell* 2016, 167(3): 684-694.e689.

490

491 37. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of
492 antiviral immunity after smallpox vaccination. *Nature Medicine* 2003, 9(9): 1131-1137.

493

494 38. Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-Virus-Based Vaccines Are
495 Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. *Viruses* 2022, 14(9):
496 1960.

497

498 39. Terajima M, Orphin L, Leporati AM, Pazoles P, Cruz J, Rothman AL, et al. Vaccinia virus-
499 specific CD8+ T-cell responses target a group of epitopes without a strong immunodominance
500 hierarchy in humans. *Human Immunology* 2008, 69(12): 815-825.

501

502 40. Anderson EJ, Lai L, Wrammert J, Kabbani S, Xu Y, Priyamvada L, et al. Plasmablast, Memory
503 B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified
504 Vaccinia Ankara Vaccine. *Vaccines* 2020, 8(1): 69.

505

506 41. Roederer M, Nozzi JL, Nason MC. SPICE: Exploration and analysis of post-cytometric
507 complex multivariate datasets. *Cytometry Part A* 2011, 79A(2): 167-174.

508

509

510 **Data availability**

511 All data supporting the findings of this study are available within the paper and its Supplementary
512 Information. Raw data are available from the corresponding author upon reasonable request
513

514 **Acknowledgments**

515 The authors thank the individuals and patients who participated in this study and Véronique Rieux
516 (ANRS-MIE) and Lucie Hardel for their help with the ANRS-VR01 trial samples.

517 **Contributors**

518 Yves Lévy, Aurélie Wiedemann, and Mathieu Surénaud conceived and designed the study. Yves
519 Lévy, Aurélie Wiedemann, Mathieu Surénaud, Mathieu Hubert, Jean-Daniel Lelièvre, and Olivier
520 Schwartz analyzed and interpreted the data. Mathieu Hubert, Alexandre Ribeiro, Cécile Rodrigues,
521 Emile Foucat, and Corinne Krief performed the experiments. José-Luis Zaragoza and Harouna
522 Diombera participated in sample and clinical data collection. Yves Lévy, Aurélie Wiedemann, and
523 Mathieu Surénaud drafted the first version and wrote the final version of the manuscript. All authors
524 approved the final version.

525 **Funding**

526 This work was supported by INSERM and the Investissements d'Avenir program, Vaccine Research
527 Institute (VRI), managed by the ANR under reference ANR-10-LABX-77-01.

528 **Declaration of interest**

529 The authors declare no conflict of interest.

530

531

532 **Materials and Methods**

533 **Participants**

534 In July 2022, a prospective, monocentric cohort clinical study enrolling MPXV infected patients and
535 individuals vaccinated with a third-generation MVA-based vaccine (IMVANEX) was initiated by the
536 Immunology Department of the Henri Mondor Hospital. The study protocol was approved by the
537 appropriate ethics committee (CPP Ile-de-France VII and IX), with approval reference 10–023
538 (infected patients) and ID RCB 2018_A01610-55 – n°CPP:18.09.09 (vaccinated patients). Written
539 informed consent was collected from each participant at enrollment. In addition, we used samples from
540 subjects enrolled in the ANRS VRI01 clinical trial, a trial performed in 2014 on 92 individuals to
541 evaluate the effectiveness of MVA-HIVB as a vaccine candidate. Each participant was injected with
542 two doses of MVA-HIVB with an eight-week interval. The protocol was approved by an ethics
543 committee (Comité de Protection des Personnes Ile-de-France V, Paris, France) and the competent
544 French health authority (Agence Nationale de Sécurité du Médicament et des Produits de Santé) and
545 was conducted in accordance with the declaration of Helsinki. All volunteers provided written and
546 signed informed consent for the trial. The trial was registered with ClinicalTrials.gov (NCT02038842)
547 and EudraCT (2012-002456-17)³².

548 **MVA and MPXV neutralization assays**

549 Seroneutralization assays against MVA and MPXV were performed as previously described³¹. Briefly,
550 a modified Vaccinia virus Ankara carrying a GFP reporter gene (MVA-GFP) was provided by ANRS-
551 MIE. A MPXV strain (MPXV/2022/FR/CMIP) was isolated from a pustular lesion of a 36- year-old
552 French man who consulted at the Medical Center of the Institut Pasteur (CMIP), in June 2022. For the
553 MVA neutralization assay, Vero E6 cells were used. The indicated concentrations of MVA-GFP were
554 mixed (ratio 1:1) with serial dilutions (from 1/30 to 1/30,000) of previously heat-inactivated (30 min at
555 56°C) plasma or serum in the presence or absence of 10% guinea pig serum as a source of
556 complement (GPC; Rockland). After incubation for 2 h at 37°C, the mixture was added to Vero E6 cell
557 monolayers. Twenty hours later, cells were stained with Hoechst (1:1,000 dilution; Invitrogen). Images
558 were acquired using an Opera Phenix high-content confocal microscope (Perkin Elmer). The GFP
559 area and number of nuclei were quantified using Harmony software (Perkin Elmer). The percentage of
560 neutralization was calculated using the GFP area as the value with the following formula:
561 $100 \times \frac{(1 - \frac{\text{value for serum}}{\text{value for "non-infected"}})}{(\frac{\text{value for "no serum"}}{\text{value for "non-}}$

562 infected”). The neutralizing activity of each plasma or serum sample was expressed as the ED50
563 (effective dose inhibiting 50% of infection). ED50 values were calculated using a reconstructed curve
564 with the percentage of neutralization at the different serum concentrations. For the MPXV
565 neutralization assay, U2OS cells were used. The indicated concentrations of MPXV were mixed (ratio
566 1:1) in a BSL-3 facility with serial dilutions of previously heat-inactivated (30 min at 56°C) plasma or
567 serum in the presence or absence of 10% GPC. Forty-eight hours later, cells were immunostained for
568 MPXV antigens with rabbit polyclonal anti-VACV antibodies (PA1-7258, Invitrogen) and an Alexa Fluor
569 488-coupled goat anti-rabbit antibody (Invitrogen). Nuclei were stained with Hoechst. Images were
570 acquired using an Opera Phenix high-content confocal microscope (PerkinElmer). The MPXV⁺ area
571 and number of nuclei were quantified using Harmony software (PerkinElmer). The neutralization titer
572 was determined as the highest plasma or serum dilution in which the MPXV⁺ area was inferior to that
573 of the “no serum” condition. The proportion of neutralizers was then evaluated by calculating the
574 percentage of individuals exhibiting a neutralizing activity > LOD (limit of detection).

575 **Specific antigens**

576 To evaluate the anti-Vaccinia and anti-Monkeypox virus cellular immune responses, screening
577 experiments (IFN- γ ELISpot) were performed using six peptide pools from Vaccinia virus strain Ankara
578 (PepMix MVA-018L, MVA-074R, MVA-093L, MVA-105L, MVA-121L, and MVA-189R) and one from
579 Vaccinia virus strain Western Reserve (PepMix VACV-L3L). These pools consist of 15-mer peptides,
580 overlapping by 11 amino acids, covering different proteins of the Vaccinia virus. In addition, the Pan-
581 Poxviridae Select PepMix, containing 127 selected epitopes (composed of 107 CD8 T-cell epitopes
582 and 20 CD4 T-cell epitopes, of which 96% are 100% conserved in MPXV and 94% are 100%
583 conserved in MVA) from the Monkeypox virus, Variola virus, and Vaccinia virus, was used. The
584 peptide pools were all purchased from JPT Peptide Technologies, Berlin, Germany. As the sequence
585 homology of Putative 21.7k protein (MVA189R) was below 90% between MVA and MPXV and as no
586 responder was observed with VACV-L3L in screening experiments, these two peptide pools were not
587 used in later experiments. The five remaining MVA peptide pools used in this study are described in
588 Supplementary Table 1.

589 **IFN- γ Elispot assay**

590 Ag-specific T cell responses were assessed using an IFN- γ ELISpot assay (ELISpot plus: Human IFN-
591 γ (ALP), Mabtech) on cryopreserved PBMCs following the manufacturer's instructions. Thawed

592 PBMCs were stimulated (100,000 cells/well) for 18 h at 37°C, 5% CO₂ with 2 µg/ml of the 6 PepMix as
593 described previously. Non-stimulated PBMCs were used as a negative control and anti-CD3- (1/2000)
594 stimulated PBMCs were used as a positive control. Spot-forming cells (SFC) were counted using an
595 AID ELISpot reader (AID Autoimmun Diagnostika GmbH) and are expressed as SFC/10⁶ cells after
596 deduction of the background (non-stimulated PBMCs). Seventy-eight samples were tested, and the
597 positivity threshold was defined as three-fold the mean of all non-stimulated PBMCs (52 SFC/10⁶
598 cells) after deduction of the background.

599 **Intracellular Staining (ICS) assay**

600 The quality of Ag-specific T-cell responses was evaluated using an intracellular cytokine staining (ICS)
601 assay on cryopreserved PBMCs. PBMCs were stimulated (18h, 37°C, 5% CO₂) with the six peptide
602 pools as described above in the presence of anti-CD28 and anti-CD49d Abs (1 µg/ml each) and
603 GolgiPlug (10 µg/ml) (BD Biosciences, Le Pont de Claix, France). Cell functionality was assessed by
604 ICS, with Boolean gating. The flow cytometry panel included a viability marker, CD3, CD4, and CD8
605 antibodies to determine the T-cell lineage, and IFN-γ, TNF, IL-2, IL-4, IL-10, IL-13 antibodies (all from
606 BD Biosciences).

607 Data were acquired using a LSRFortessa four-laser (488, 640, 561, and 405 nm) flow cytometer (BD
608 Biosciences) and analyzed using FlowJo software, version 9.9.5 (Tree Star). Distributions were plotted
609 with SPICE version 5.22, downloaded from <http://exon.niaid.nih.gov/spice>⁴¹

610 **Statistical analysis**

611 Figures and statistical analyses were conducted using GraphPad Prism 9. Statistical significance
612 between groups was calculated using the tests indicated in each figure legend. No statistical methods
613 were used to predetermine sample size.

614

615

616 **Figure legends**

617 **Figure 1. Neutralizing antibodies induced by MPXV infection and the MVA-BN and experimental**
618 **MVA-HIVB vaccines. A.** Seroneutralization of MVA-GFP and **B.** MPXV by sera from MPXV-infected
619 patients (Conv.) (n=8) and MVA-BN- and MVA-HIVB vaccinees in the presence or absence of 10%
620 guinea pig complement as a source of complement. Younger and older individuals were distinguished
621 using 1980 as a cut-off year. In the vaccine groups, individuals were separated according to their
622 vaccination status at the time of sample collection (1d: after the first dose (n=20 and n=15 for
623 individuals born <1980 and >1980, respectively); 2d: after the second dose (n=18 and n=10, for the
624 MVA-BN and MVA-HIVB vaccines, respectively). Anti-MVA neutralizing activity is expressed as the
625 median effective dose (ED50), corresponding to the last dilution of plasma that reduces MVA-GFP
626 infection by 50%. Anti-MPXV neutralizing activity is expressed as the neutralizing titer, corresponding
627 to the highest dilution for which neutralization was observed. The dotted line represents the limit of
628 detection (LOD). The proportion of neutralizers was evaluated by calculating the percentage of
629 individuals exhibiting a neutralizing activity > LOD. Kruskal Wallis' test was used for comparisons in
630 assays performed with complement.

631 **Figure 2. Frequency and magnitude of T-cell responses against the Pan-PXV pool of peptides**
632 **induced by MPXV infection and the MVA-BN and MVA-HIVB vaccines. A.** Magnitude of T-cell
633 responses (SFC/10⁶ cells) of MPXV-infected patients (Conv) (n=8) and MVA-BN vaccinees (n=20 and
634 n=15 after the first dose (1d) for individuals born <1980 and >1980, respectively, n=18 after the
635 second dose (2d)), and MVA-HIVB vaccinees (n=10) against the Pan-PXV peptide pool measured by
636 the IFN- γ ELISPOT assay. Background-subtracted results are presented. The dotted line represents
637 the positivity threshold. **B.** T-cell responses (SFC/10⁶ cells) of MPXV-infected patients (Conv) (n=8),
638 fully vaccinated MVA-BN individuals (n=38), and MVA-HIVB vaccinees (n=10) against the Pan-PXV
639 peptide pool measured by IFN- γ ELISPOT assay. Background-subtracted results are shown, with the
640 dotted line representing the positivity threshold. **C.** Magnitude and functional profile of Pan-specific
641 CD8⁺ T-cell responses of MPXV-infected patients (Conv) (n=6) or MVA-BN vaccinees (n=10 and n=15
642 after the first dose (1d) for individuals born <1980 and >1980, respectively; n=14 after the second
643 dose (2d)) and MVA-HIVB vaccinees (n=10) after overnight stimulation with the Pan-PXV peptide
644 pool. The median frequency of total cytokines detected (Cyt.Tot.) (IFN- γ ±IL-2±TNF)±IQR is shown.
645 Wilcoxon comparison tests were used for statistical analysis. In the pie charts, responses are color

646 coded according to the combinations of cytokines produced. The arcs identify cytokine-producing
647 subsets (IFN- γ , IL-2, and TNF) within the CD8⁺ T-cell populations. **D.** Magnitude of Pan-specific CD8⁺
648 T-cell responses of MPXV-infected (Conv) patients (n=6), fully vaccinated MVA-BN individuals (n=24),
649 and MVA-HIVB vaccinees (n=10) after overnight stimulation with the Pan-PXV peptide pool. The
650 median frequency of total cytokines detected (Cyt.Tot.) (IFN- γ ±IL-2±TNF) ± IQR is presented.
651 Background-subtracted results are shown. Kruskal-Wallis and Dunn's comparison tests were used for
652 statistical analysis.

653 **Figure 3. Frequency and magnitude of T-cell responses against the MVA peptide pool induced**
654 **by MPXV infection and the MVA-BN and experimental MVA-HIVB vaccines. A.** Magnitude of T-
655 cell responses (SFC/10⁶ cells) of MPXV-infected patients (Conv) (n=8) and MVA-BN vaccinees (n=20
656 and n=15 after the first dose (1d) for individuals born <1980 and >1980, respectively, n=18 after the
657 second dose (2d)) and MVA-HIVB vaccinees (n=18) against the MVA global peptide pool (sum of 5
658 peptide pools) measured by IFN- γ ELISPOT assay. Background-subtracted results are presented. The
659 dotted line represents the positivity threshold. Medians ± IQR are shown. **B.** Frequency of IFN- γ
660 responders measured by ELISPOT assay to the MVA-18L, -121L, -093L, -074R, and -105L individual
661 peptide pools in each group of individuals. **C.** Breadth of T-cell responses against the MVA-18L, -
662 121L, -093L, -074R, and -105L peptide pools among IFN- γ responders.

663 **Figure 4. Polyfunctional CD4 and CD8 T-cell responses against the MVA-121L and MVA-018L**
664 **peptide pools induced by MVA vaccination. A.** Magnitude and functional composition of MVA-
665 121L-specific CD4⁺ T-cell responses of MVA-BN and MVA-HIVB vaccinees. **B.** Magnitude and
666 functional composition of MVA-121L- and MVA-018L-specific CD8⁺ T-cell responses of MVA-BN and
667 MVA-HIVB vaccinees (n=10 and n=15 after the first dose (1d) for individuals born <1980 and >1980,
668 respectively and n=14 after the second dose (2d)) for MVA-BN vaccinees; and n=10 for MVA-HIVB
669 vaccinees) after overnight stimulation with five pools of overlapping peptides covering different regions
670 of MVA. The median frequency of total cytokines (Cyt.Tot.) (IFN- γ ±IL-2±TNF) ± IQR is shown.
671 Friedman and Dunn's multiple comparison tests were used for statistical analysis. In the pie charts,
672 responses are color coded according to the combinations of cytokines produced. The arcs identify
673 cytokine-producing subsets within the CD4⁺ T-cell populations (IFN- γ , IL-2, IL-4/IL-13/IL-10, and TNF)
674 and CD8⁺ T-cell populations (IFN- γ , IL-2, and TNF).

675 **Figure 5. Neutralizing antibodies and T-cell immune responses elicited by MVA-BN vaccination**
676 **in HIV-positive and HIV-negative Individuals. A.** Seroneutralization of MVA-GFP (left panel) by sera
677 from HIV⁻ and HIV⁺ MVA-BN vaccinees in the presence of 10% guinea pig complement as a source of
678 complement. The anti-MVA neutralizing activity is expressed as the median effective dose (ED₅₀),
679 corresponding to the last dilution of plasma that reduces MVA-GFP infection by 50%. Magnitude of T-
680 cell responses (SFC/10⁶ cells) (right panel) of HIV⁻ and HIV⁺ MVA-BN vaccinees against the MVA
681 peptide pool measured by IFN- γ ELISPOT assay. Background-subtracted results are presented. **B**
682 Seroneutralization of MPXV (left panel) by sera from HIV⁻ and HIV⁺ MVA-BN-vaccinees in the
683 presence of 10% guinea pig complement as a source of complement. Anti-MPXV neutralizing activity
684 is expressed as the neutralizing titer, corresponding to the highest dilution for which neutralization was
685 observed. Magnitude of T-cell responses (SFC/10⁶ cells) (right panel) of HIV⁻ and HIV⁺ MVA-BN
686 vaccinees against the Pan-PXV peptide pool measured by IFN- γ ELISPOT assay. (HIV⁻ n=21, HIV⁺
687 n=17, squares: individuals born before 1980 receiving one dose of MVA-BN, triangles: individuals born
688 after 1980 receiving two doses of MVA-BN). Medians \pm IQR are shown. The Mann-Whitney test was
689 used for comparisons.

690

691

692

693



694

695



696




697




A



B







A**B****C**


A

MVA



B

MPXV



Pan-PXV

